Clinical trials: Juvenile Arthritis
Septic Arthritis, Juvenile Idiopathic Arthritis
ARTEMIS Synovial Markers in Arthritis Childhood
The aim of this study is to find markers that could differentiate infectious and inflammatory arthritis. The investigators want to find markers by differential analysis by compare synovial fluids of septic and inflammatory…
- Trial name
- ARTEMIS (NCT02505828)
- Testing
- Articular punction, salivary samples, blood sample
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Montpellier
Systemic Juvenile Idiopathic Arthritis
An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
This two-part open-label, multi-arm, non-comparative study will collect long-term safety, efficacy and tolerability data from patients who were responsive to canakinumab from study CACZ885G2301E1 (Cohort 1), and from patients who…
- Trial name
- β-SPECIFIC 4Pa (NCT01676948)
- Testing
- ACZ885, Canakinumab
- Sponsor
- Novartis Pharmaceuticals
Juvenile Idiopathic Arthritis, ALL
Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia
Methotrexate is a cornerstone in the treatment of childhood leukemia. When given in high-dose as part of the initial phase of treatment, gastrointestinal toxicity is a known problem.
- Trial name
- NCT02528435
- Volunteers
- 145 people
- Sponsor
- University of Aarhus
Juvenile Idiopathic Arthritis
Biomarkers in Saliva in Children With Juvenil Idiopathic Arthritis
Purpose and aims This as a pilot study that aims to investigate which inflammatory biomarkers can be found in saliva in children with Juvenile Idiopathic Arthritis (JIA).
- Trial name
- NCT02223195
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Folktandvården Stockholms län AB
Juvenile Idiopathic Arthritis
Cellular and Molecular Adaptations to Exercise-induced Inflammatory Response in Children With Autoimmune Diseases
Juvenile idiopathic arthritis (JIA) is a chronic disease characterized by persistent joint inflammation. The immune system disruption that leads to overproduction of pro-inflammatory cytokines (TNF-α, IL-1, IL-6) is a cascade of…
- Trial name
- AJI-APA (NCT02502539)
- Testing
- Controlled physical activity
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Clermont-Ferrand
Juvenile Idiopathic Arthritis
Pain in Juvenile Arthritis
Juvenile idiopathic arthritis (JIA) is the most common rheumatologic disease in children. The main symptoms of JIA, which are often the primary focus of treatment, include joint swelling, stiffness, and tenderness.
- Trial name
- NCT07217782
- Testing
- Pressure pain thresholds (measured in kilopascal), Cold pain tolerance (duration in seconds)
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Juvenile Idiopathic Arthritis
Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis
Primary Objective of the study: the purpose of this extension study was to determine the safety of Givinostat in a long term treatment of patients who participated in DSC/08/2357/36 study with good results (clinical benefit at…
- Trial name
- NCT01557452
- Testing
- Givinostat
- Where
- Czechia
- Volunteers
- 1 people
- Sponsor
- Italfarmaco
Juvenile Idiopathic Arthritis
Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]
This surveillance is conducted to survey the followings under the post marketed drug utilization on the patients who are administrated ENBREL as a treatment for active polyarticular JIA. 1.
- Trial name
- Enbrel-JIA (NCT01145352)
- Testing
- Etanercept (genetical recombination)
- Where
- Japan
- Volunteers
- 113 people
- Sponsor
- Pfizer
Juvenile Idiopathic Arthritis
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA
Polyarticular juvenile idiopathic arthritis (Poly JIA) is a form of juvenile arthritis, which is a chronic disease affecting approximately 250,000 people younger than 16 years of age.
- Trial name
- NCT00792233
- Testing
- Withdrawal of anti-TNF therapy
- Where
- 16 sites in United States
- Volunteers
- 137 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Arthritis, Juvenile Rheumatoid, Crohn Disease
Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease
The investigators hypothesize that the anabolic effects of Genotropin (somatropin) will improve the height and weight of children with inflammatory based chronic illness who have failed to grow despite receiving adequate…
- Trial name
- NCT00511329
- Testing
- somatropin [rDNA origin] for injection
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Nationwide Children's Hospital
Spondylarthropathies
Evolution of Intestinal Microbiota in Patients With Juvenile Spondylarthropathy According to Typology of Treatment
Idiopathic juvenile arthritis includes 20% of patients with arthritis with enthesitis or juvenile spondyloarthropathy. This is treated with anti-inflammatory drugs and then followed by biotherapy with DMARDs (Drugs Modifying the…
- Trial name
- MESAJ (NCT04540432)
- Testing
- Stool collection at the patient's home., Blood test
- Where
- 4 sites in France
- Volunteers
- 25 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Juvenile Idiopathic Arthritis
Human Factors Study of Methotrexate Prefilled Pen (50 mg/mL) in Patients With Juvenile Idiopathic Arthritis
This study is planned to evaluate the human factor (HF)/usability of pediatric or adolescent JIA patients and the caregivers of Juvenile Idiopathic Arthritis (JIA) patients with the Methotrexate Prefilled Pen (including a label…
- Trial name
- NCT02052167
- Testing
- methotrexate prefilled pen
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- medac GmbH
Juvenile Idiopathic Arthritis
Efficacy Study Of Tofacitinib In Pediatric JIA Population
Evaluate efficacy, safety and tolerability of tofacitinib in pediatric JIA patients.
- Trial name
- NCT02592434
- Testing
- CP-690,550 (tofacitinib)
- Where
- 103 sites in United States, Argentina and 12 more
- Volunteers
- 225 people
- Sponsor
- Pfizer
Anterior Uveitis, Arthritis, Juvenile Idiopathic
Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis
This study will examine the safety and effectiveness of a monoclonal antibody called humanized anti-Tac (HAT, also called daclizumab) to treat children and adolescents with uveitis (chronic inflammatory eye disease) associated…
- Conditions
- Anterior Uveitis, Arthritis, Juvenile Idiopathic, Iritis, Immunosuppression
- Trial name
- NCT00130637
- Testing
- Daclizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
Rheumatoid Arthritis, Ankylosing Spondylitis
PatientSpot Formerly Known as ArthritisPower
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout
- Trial name
- NCT03840928
- Where
- United States
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Global Healthy Living Foundation
Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.
- Trial name
- NCT06668181
- Testing
- Bimekizumab
- Where
- 23 sites in Canada, France and 4 more
- Volunteers
- 40 people
- Sponsor
- UCB Biopharma SRL
Juvenile Idiopathic Arthritis
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.
- Trial name
- NCT01500551
- Testing
- Tofacitinib
- Where
- 104 sites in United States, Argentina and 17 more
- Volunteers
- 302 people
- Sponsor
- Pfizer
Juvenile Idiopathic Arthritis
Efficiency of Supervised Exercise Program Versus Mobile-Based Exercise Program in Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis (JIA) is a heterogeneous, idiopathic, chronic inflammatory, rheumatic disease that is most common in childhood and is thought to involve immunological mechanisms in its etiopathogenesis.
- Trial name
- NCT06193681
- Testing
- Pedi@ctivity Exercise Mobile Application Exercise Program, Supervised Exercise Group
- Where
- Turkey (Türkiye)
- Volunteers
- 54 people
- Sponsor
- Istanbul University - Cerrahpasa
Osteoarthritis, Rheumatoid Arthritis
Randomized Fixed Bearing vs Mobile Bearing Cruciate Retaining TKA
The purpose of this study is to evaluate the clinical performance of the rotating platform and fixed bearing implants in patients undergoing primary total knee replacement.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Post-traumatic Arthritis, Juvenile Rheumatoid Arthritis
- Trial name
- NCT00289094
- Testing
- Total Knee Replacement
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- DePuy Orthopaedics
SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis
SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis
Since june 2021, vaccination against the SARS-Cov2 virus is recommanded in France to all children from 12 to 18 years old. In the specific population of teenagers living with juvenile arthritis, the vaccine seems to be safe and…
- Trial name
- VACOVAJI (NCT05547451)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Nantes University Hospital